Evidence map›Paper›PMID 39114701›Full record

ReviewAmerican journal of translational research2024

Efficacy of sulodexide in treating idiopathic membranous nephropathy among Chinese patients: a meta-analysis.

Tao Wang, Jiwen Xu, Yiming Sun, Li Liu, Yue Li, Xiaojun Cai, Ming Chen, Yingying Fang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tao WangDepartment of Endocrinology, Heilongjiang Academy of Traditional Chinese Medicine Harbin, Heilongjiang, China.
Jiwen XuSchool of Basic Medical Sciences, Heilongjiang University of Chinese Medicine Harbin, Heilongjiang, China.
Yiming SunDepartment of Andrology, Heilongjiang Academy of Traditional Chinese Medicine Harbin, Heilongjiang, China.
Li LiuDepartment of Gynecology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine Harbin, Heilongjiang, China.
Yue LiDepartment of Andrology, Heilongjiang Academy of Traditional Chinese Medicine Harbin, Heilongjiang, China.
Xiaojun CaiDepartment of Endocrinology, Heilongjiang Academy of Traditional Chinese Medicine Harbin, Heilongjiang, China.
Ming ChenDepartment of Nephropathy, Heilongjiang Academy of Traditional Chinese Medicine Harbin, Heilongjiang, China.
Yingying FangDepartment of Hepatobiliary Spleen and Stomach Disease, Heilongjiang Academy of Traditional Chinese Medicine Harbin, Heilongjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy of Sulodexide in treating idiopathic membranous nephropathy (IMN) in the Chinese population.

methodsWe systematically reviewed all eligible randomized clinical trials (RCTs) conducted in China that investigated the effects of Sulodexide on IMN. Three RCTs published between 2013 and 2022 were included, encompassing a total of 146 patients. The primary outcomes evaluated were changes in urine total protein (UTP), serum albumin (ALB), cholesterol (CHOL), and fibrinogen (FIB) levels.

resultsStatistically significant differences were observed in the Sulodexide treatment group compared to the control group for the following parameters: reduction in UTP and CHOL, increase in ALB, and reduction in FIB levels.

conclusionSulodexide, when combined with conventional therapy, effectively reduces UTP and CHOL levels, decreases FIB levels, and increases ALB in Chinese patients with IMN.

Indexed as

idiopathic membranous nephropathymeta-analysisSulodexidesystematic review

Identifiers

PMID39114701
PMCPMC11301453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.